Skip to main
GRI

GRI Stock Forecast & Price Target

GRI Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GRI Bio is a clinical-stage biotech company with a strong pipeline of potential treatments targeting serious diseases associated with dysregulated immune responses, including inflammatory, fibrotic, and autoimmune disorders. The company's lead drug candidate, GRI-0621, has shown promising results in Phase 2a trials, with positive biomarker data and a clean safety profile. This drug has the potential to differentiate itself in the market by not only slowing down but even reversing the underlying causes of IPF. With additional programs in development, potential partnerships, and a large addressable market, the company has significant upside potential. However, investors should consider risks such as potential funding issues, clinical trial failures, and commercialization challenges. Based on a clinical net present value (NPV) model, a valuation of $10 per share may underestimate the long-term potential for GRI Bio.

Bears say

GRI Bio is a clinical-stage biopharmaceutical company focused on developing treatments for immune-related diseases through their novel small molecule therapies GRI-0621 and GRI-0803. While the company has displayed positive topline data and raised a decent amount of capital, their recent financial performance and on-going clinical studies place them in a precarious position, leading to the negative outlook from this financial analyst.

GRI has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRI Bio Inc (GRI) Forecast

Analysts have given GRI a Strong Buy based on their latest research and market trends.

According to 2 analysts, GRI has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRI Bio Inc (GRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.